Fortress Biotech, Inc. - 31 Dec 2022 Form 4 Insider Report for AVENUE THERAPEUTICS, INC. (ATXI)

Role: 10%+ Owner
Signature: /s/ Samuel Berry, General Counsel and Authorized Agent
Issuer symbol: ATXI
Transactions as of: 31 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 04 Jan 2023, 16:49:03 UTC
Previous filing: 31 May 2024
Next filing: 06 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATXI	COMMON STOCK, PAR VALUE $0.0001	Award	$0	+90,909	+38%	$0.000000	330,245	31 Dec 2022	Direct	F1, F4
transaction	ATXI	COMMON STOCK, PAR VALUE $0.0001	Award	$0	+231,316	+70%	$0.000000	561,561	03 Jan 2023	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ATXI	Class A Preferred Stock, par value $0.0001						250,000	31 Dec 2022	Common Stock	16,666		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.
F2	The Reporting Person is entitled to an annual dividend on its outstanding Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual dividend.
F3	The Issuer's Class A Preferred Stock is convertible at a fifteen to one ratio at any time at the option of the Reporting Person into shares of the Issuer's Common Stock and has no expiration date.
F4	Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.